There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CytomX Therapeutics Inc (CTMX) and Allena Pharmaceuticals Inc (ALNA) with bullish sentiments.
CytomX Therapeutics Inc (CTMX)
Cowen & Co. analyst Boris Peaker initiated coverage with a Buy rating on CytomX Therapeutics Inc today. The company’s shares closed on Friday at $15, close to its 52-week low of $12.75.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.0% and a 42.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
CytomX Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $26.50.
See today’s analyst top recommended stocks >>
Allena Pharmaceuticals Inc (ALNA)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Allena Pharmaceuticals Inc. The company’s shares closed on Friday at $8.11.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 26.0% and a 48.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on Allena Pharmaceuticals Inc is a Moderate Buy with an average price target of $38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
